Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 17, 2026, 6:06 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Rabeprazole 20 mg Clear all
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Relative Bioavailability Study Evaluating Two New Encorafenib Formulations

NCT05446142
View directory record Official record
Conditions
Healthy
Interventions
Encorafenib capsule formulation (CAP), Encorafenib first formulation, Encorafenib second formulation, Rabeprazole tablet
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Feb 22, 2024 · Synced Sep 17, 2026, 6:06 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate the Effect on 24-hour, Intragastric pH of RAB ER 50-mg Capsules Compared With Esomeprazole (Nexium) 40 mg Capsules and Rabeprazole (Aciphex) 20-mg Tablets

NCT01153659
View directory record Official record
Conditions
Healthy
Interventions
E3810, Aciphex (rabeprazole), Nexium (esomeprazole)
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2010
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Oct 31, 2013 · Synced Sep 17, 2026, 6:06 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Role of Pain Modulation in GERD Patients Who Failed Standard Dose PPI

NCT00539240
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
Rabeprazole 20mg, placebo dinner and bedtime, Rabeprazole 20 mg two times, Placebo at bedtime, Rabeprazole 20mg,placebo dinner ,Low dose Tricyclic Antidepressant
Drug
Lead sponsor
US Department of Veterans Affairs
Federal
Eligibility
18 Years to 80 Years
Enrollment
236 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2011
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 17, 2014 · Synced Sep 17, 2026, 6:06 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fed Study of Rabeprazole Sodium Tablets 20 mg and Aciphex® Tablets 20 mg

NCT00649493
View directory record Official record
Conditions
Healthy
Interventions
Rabeprazole Sodium Tablets 20 mg, Aciphex® Tablets 20 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
8 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Apr 22, 2024 · Synced Sep 17, 2026, 6:06 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Effects of Proton-pump Inhibitor on Acalabrutinib Capsule When Administered Orally With COCA-COLA in Healthy Participants

NCT04489797
View directory record Official record
Conditions
Infectious Disease
Interventions
Acalabrutinib, Rabeprazole
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Anaheim, California
Source: ClinicalTrials.gov public record
Updated Oct 29, 2020 · Synced Sep 17, 2026, 6:06 PM EDT
Completed Phase 2 Interventional Results available

Maintenance Intermittent Therapy for Symptomatic GERD Patients

NCT00165841
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
Rabeprazole 20 mg
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
200 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2008
U.S. locations
1
States / cities
Vista, California
Source: ClinicalTrials.gov public record
Updated May 19, 2013 · Synced Sep 17, 2026, 6:06 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Food Study of Rabeprazole Sodium Delayed-Release Tablets 20 mg to Aciphex® Tablets 20 mg

NCT00649194
View directory record Official record
Conditions
Healthy
Interventions
Rabeprazole Sodium Delayed-Release Tablets 20 mg, Aciphex® Tablets 20 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Sep 17, 2026, 6:06 PM EDT
Completed Phase 4 Interventional

Comparison of the Nighttime Effects of Two Different Drugs on Subjects With GERD

NCT00304421
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
rabeprazole, pantoprazole
Drug
Lead sponsor
VA Greater Los Angeles Healthcare System
Federal
Eligibility
18 Years to 65 Years
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 16, 2007 · Synced Sep 17, 2026, 6:06 PM EDT
Completed Phase 2 Interventional

A Study to Evaluate the Efficacy and Safety of Arbaclofen Placarbil (XP19986) as Adjunctive Therapy in Subjects With Gastroesophageal Reflux Disease (GERD)

NCT00978016
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
arbaclofen placarbil-Cohort 1, Placebo-Cohort 5, arbaclofen placarbil-Cohort 2, arbaclofen placarbil-Cohort 3, arbaclofen placarbil-Cohort 4, PPI
Drug
Lead sponsor
XenoPort, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
460 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
62
States / cities
Huntsville, Alabama • Chandler, Arizona • Mesa, Arizona + 56 more
Source: ClinicalTrials.gov public record
Updated Feb 20, 2021 · Synced Sep 17, 2026, 6:06 PM EDT
Completed Phase 4 Interventional

Role of Pain Modulation in GERD Patients Who Failed Standard Dose Proton Pump Inhibitors (PPI)

NCT00251732
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
Standard dose (once daily) PPI plus low-dose antidepressant, Double dose PPI plus evening placebo, Rabeprazole , placebo, placebo
Drug
Lead sponsor
University of Arizona
Other
Eligibility
18 Years to 75 Years
Enrollment
150 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2010
U.S. locations
1
States / cities
Tucson, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 18, 2010 · Synced Sep 17, 2026, 6:06 PM EDT
Completed Phase 2Phase 3 Interventional

Laryngopharyngeal Reflux and Proton Pump Inhibitor (PPI) Treatment

NCT00204698
View directory record Official record
Conditions
Laryngopharyngeal Reflux
Interventions
Aciphex
Drug
Lead sponsor
University of Utah
Other
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2006
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jan 15, 2008 · Synced Sep 17, 2026, 6:06 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Investigate the Effect of Increased Gastric pH on the Oral Bioavailability of the Orexin-2 Receptor Antagonist JNJ-42847922 in Healthy Participants

NCT02475161
View directory record Official record
Conditions
Healthy
Interventions
JNJ-42847922, Rabeprazole
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years to 55 Years
Enrollment
16 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Feb 2, 2025 · Synced Sep 17, 2026, 6:06 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

HMPL-523 Food Effect and Proton Pump Inhibitor Study

NCT05571787
View directory record Official record
Conditions
Relapsed or Refractory Lymphoma
Interventions
HMPL-523, Rabeprazole
Drug
Lead sponsor
Hutchmed
Industry
Eligibility
18 Years to 55 Years
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Feb 22, 2023 · Synced Sep 17, 2026, 6:06 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Sleep Disorders and Gastroesophageal Reflux Disease (GERD)

NCT00287391
View directory record Official record
Conditions
Insomnia, GERD
Interventions
Rabeprazole
Drug
Lead sponsor
University of North Carolina
Other
Eligibility
18 Years to 75 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2004 – 2006
U.S. locations
1
States / cities
Chapel Hill, North Carolina
Source: ClinicalTrials.gov public record
Updated Apr 26, 2007 · Synced Sep 17, 2026, 6:06 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study of Maribavir Pediatric Formulation in Healthy Adult Participants

NCT05918822
View directory record Official record
Conditions
Healthy Volunteers
Interventions
Maribavir Commercial Tablet Formulation, Maribavir Pediatric Powder-for-oral Suspension Formulation, Rabeprazole
Drug
Lead sponsor
Takeda
Industry
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Sep 25, 2024 · Synced Sep 17, 2026, 6:06 PM EDT
Completed Phase 1 Interventional

A Pharmacokinetics (PK) Study of the Effects Rabeprazole and Rifampin on Dabrafenib in Subjects With BRAF V600 Mutation Positive Tumors

NCT01954043
View directory record Official record
Conditions
Cancer
Interventions
Dabrafenib 150 mg twice a day (BID), Rabeprazole 40 mg once daily (OD), Rifampin 600 mg OD
Drug
Lead sponsor
GlaxoSmithKline
Industry
Eligibility
18 Years and older
Enrollment
23 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2016
U.S. locations
3
States / cities
Goodyear, Arizona • Dallas, Texas • Tacoma, Washington
Source: ClinicalTrials.gov public record
Updated Nov 13, 2017 · Synced Sep 17, 2026, 6:06 PM EDT
Completed Phase 1 Interventional

A Study of GDC-0134 to Determine Initial Safety, Tolerability, and Pharmacokinetic Parameters in Participants With Amyotrophic Lateral Sclerosis

NCT02655614
View directory record Official record
Conditions
Amyotrophic Lateral Sclerosis
Interventions
GDC-0134, Placebo, Rabeprazole, Midazolam, Caffeine
Drug
Lead sponsor
Genentech, Inc.
Industry
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2020
U.S. locations
8
States / cities
San Francisco, California • Jacksonville, Florida • Miami, Florida + 5 more
Source: ClinicalTrials.gov public record
Updated Aug 5, 2020 · Synced Sep 17, 2026, 6:06 PM EDT
Completed Phase 2 Interventional Results available

Treatment of Gastroesophageal Reflux Disease in 12-16 Year Old Patients With Rabeprazole

NCT00132496
View directory record Official record
Conditions
Gastroesophageal Reflux Disease
Interventions
rabeprazole sodium
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
12 Years to 16 Years
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2006
U.S. locations
25
States / cities
Longmont, Colorado • Fort Lauderdale, Florida • New Port Richey, Florida + 21 more
Source: ClinicalTrials.gov public record
Updated Dec 2, 2009 · Synced Sep 17, 2026, 6:06 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study Of Three Different Stomach Acid Reducing Agents When Given With Palbociclib (PD-0332991) And Food

NCT02097329
View directory record Official record
Conditions
Healthy
Interventions
palbociclib commercial free base, famotidine, rabeprazole, antacid
Drug
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
27 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jun 18, 2014 · Synced Sep 17, 2026, 6:06 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Fasting Study of Rabeprazole Sodium Delayed-Release Tablets 20 mg to Aciphex® Delayed-Release Tablets 20 mg

NCT00648349
View directory record Official record
Conditions
Healthy
Interventions
Rabeprazole Sodium Delayed-Release Tablets 20 mg, Aciphex® Delayed-Release Tablets 20 mg
Drug
Lead sponsor
Mylan Pharmaceuticals Inc
Industry
Eligibility
18 Years and older
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003
U.S. locations
1
States / cities
Fargo, North Dakota
Source: ClinicalTrials.gov public record
Updated Apr 23, 2024 · Synced Sep 17, 2026, 6:06 PM EDT
Completed Phase 2 Interventional

Post-nasal Drainage as an Extraesophageal Manifestation of Reflux

NCT00199953
View directory record Official record
Conditions
Postnasal Drainage
Interventions
Rabeprazole 20 mg twice a day for 90-day period treatment
Drug
Lead sponsor
Medical College of Wisconsin
Other
Eligibility
18 Years to 70 Years
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2007
U.S. locations
1
States / cities
Milwaukee, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jan 29, 2017 · Synced Sep 17, 2026, 6:06 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of Acalabrutinib Suspension to Evaluate Relative Bioavailability and Proton-pump Inhibitor Effect in Healthy Volunteers

NCT04435483
View directory record Official record
Conditions
Pharmacokinetics, Bioavailability
Interventions
Acalabrutinib Treatment A, Acalabrutinib Treatment B, Acalabrutinib Treatment C
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Jul 21, 2020 · Synced Sep 17, 2026, 6:06 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Evaluate the Effects of Famotidine or Rabeprazole on the PK of Nirogacestat

NCT07171619
View directory record Official record
Conditions
Healthy
Interventions
Nirogacestat, Nirogacestat and Famotidine, Nirogacestat and Rabeprazole
Drug
Lead sponsor
SpringWorks Therapeutics, Inc., a healthcare company of Merck KGaA, Darmstadt, Germany
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
24 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025
U.S. locations
1
States / cities
Cincinnati, Ohio
Source: ClinicalTrials.gov public record
Updated May 7, 2026 · Synced Sep 17, 2026, 6:06 PM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Evaluate Relative Bioavailability, Proton Pump Inhibitor (PPI) (Rabeprazole) Effect, Food Effect and Particle Size Effect of New Acalabrutinib Tablet in Healthy Subjects

NCT04488016
View directory record Official record
Conditions
Bioavailability, B-cell Lymphoid Cancer
Interventions
Treatment A- Part 1, Treatment B- Part 1, Treatment C - Part 1, Treatment D- Part 1, Treatment A-Part 2, Treatment B - Part 2, Treatment C - Part 2, Treatment D - Part 2
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years to 55 Years
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Feb 2, 2021 · Synced Sep 17, 2026, 6:06 PM EDT